- Liraglutide, a GLP-1 receptor agonist, shows promise in reducing monthly migraine days in patients with obesity.
- The study presented at the 11th Congress of the European Academy of Neurology reported significant reduction in monthly headache days and improved Migraine Disability Assessment scores.
- The treatment's weight-independent effect on migraine reduction was noted, with no significant association between BMI reduction and headache frequency.
- Mild gastrointestinal side effects, such as nausea and constipation, were observed in 38% of patients but did not lead to discontinuation of liraglutide.
- Potential mechanisms for liraglutide's efficacy in migraine management include reduced cerebrospinal fluid production and intracranial pressure, as proposed by the investigators.
- Larger randomized controlled trials are recommended to confirm these findings and explore the therapeutic potential of GLP-1 receptor agonists in migraine management.
Liraglutide Linked to Fewer Migraine Days
Conexiant
June 24, 2025
